Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
The Saint Regis Mohawk Tribe, the owner of dry eye disease treatment Restasis (cyclosporine ophthalmic emulsion), has hit back at Mylan for questioning its sovereign immunity.   24 October 2017
Big Pharma
Patentees should ensure their applications meet the plausibility standard right from the start, says Iain Armstrong of HGF, who investigates one of the developing challenges facing patentability in the life sciences field.   24 October 2017
Americas
If biotech companies in Brazil understand that they can use both plant variety and patent protection in certain cases, their ability to innovate may improve, says Gabriel Di Blasi of Di Blasi, Parente & Associados.   24 October 2017
Big Pharma
The EU General Court has affirmed a decision that a trademark application for ‘SeboCalm’ is confusingly similar to the earlier word mark ‘Sebotherm’.   23 October 2017
Americas
A San Diego-based company has announced plans to sell a generic version of Allergan’s dry eye disease treatment Restasis (cyclosporine ophthalmic emulsion), just days after four patents covering the drug were invalidated.   23 October 2017
Big Pharma
Alnylam Pharmaceuticals and The Medicines Company UK are facing a claim for declaratory relief over supplementary protection certificates requested by biotech company Silence Therapeutics.   20 October 2017
Big Pharma
Europe’s highest court has found that in parallel lawsuits dealing with an identical trademark, the first court must take priority over the second—but not in all cases.   19 October 2017
Americas
Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.   19 October 2017
Americas
The Broad Institute of Harvard and MIT has signed a patent licensing deal with DuPont Pioneer to provide CRISPR/Cas9 technology to agricultural researchers and producers.   19 October 2017
Africa
CPA Global has found that Sanofi files the most patents covering human gene therapy and also spends the most on them overall.   18 October 2017